ImmunoGen, a biopharma that develops targeted anticancer therapeutics, has appointed James O'Leary as VP, chief medical officer. O'Leary will lead the clinical development of ImmunoGen's product candidates. ImmunoGen has collaborated with Genentech, Sanofi-Aventis, Biogen Idec, Bayer HealthCare and Amgen.
Cynvec LLC, a biopharma focused on developing cancer therapies that harness the apoptotic ability of the Sindbis viral vector, has appointed Frank Stonebanks as president and CEO, effective immediately. Stonebanks has previously worked at Johnson & Johnson and led the oncology biologics business unit at Centocor.